Navigation Links
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Date:5/5/2011

ent of BESST and receipt of top-line data for POSIDUR, possible licensing transactions relating to TRANSDUR-Sufentanil, future development activities regarding ELADUR, anticipated commencement of a new Phase I trial for ORADUR-ADHD and our other drug candidates and the potential benefits and uses of our drug candidates are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K on March 3, 2011 under the heading "Risk Factors."DURECT CORPORATIONBALANCE SHEET DATA(in thousands)As ofAs ofMarch 31, 2011December 31, 2010 (1)(unaudited)ASSETSCurrent assets:Cash and cash equivalents$
4,830$
,437Short-term investments33,54
'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
2. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
3. DURECT Corporation Announces Third Quarter 2008 Financial Results
4. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
5. Techne Corporation Declares Dividend
6. Techne Corporation Announces Acquisition
7. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
8. Vestaron Corporation Announces New Leadership
9. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
10. Every Day is Earth Day for Yulex Corporation
11. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , AURORA, Ontario, Sept. 8 Helix BioPharma Corp. (TSX, ... announced private placement of 6,625,000 units at $2.05 per unit. ... and one common share purchase warrant, with each common share purchase warrant ... the Company at a price of $2.87 for up to three years ...
... , CAMBRIDGE, Mass., Sept. 8 ... the development of next-generation cellulosic ethanol and high-performance specialty enzymes, ... of the Company,s common stock will take effect after market ... continue to trade on the NASDAQ Global Market under the ...
... , FORT LAUDERDALE, Fla., Sept. 8 South Florida ... launched an important joint event with the state,s life sciences organization, ... Lauderdale on August 27, to hear experts from Scripps Florida, University ... and information technology. , , Presentations ...
Cached Biology Technology:Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3Verenium Announces Reverse Stock Split to Take Effect September 9 2Verenium Announces Reverse Stock Split to Take Effect September 9 3Verenium Announces Reverse Stock Split to Take Effect September 9 4South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 2South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... a protein critical to enabling the brain to talk to ... researchers report. The finding that an antibody to ... brain-muscle interaction helps explain why as many as 10 percent ... muscle weakness, yet their blood provides no clue of the ...
... of brain cell that tamps down stem cell activity ... progeny, Johns Hopkins researchers report. Understanding how these new ... how to behave is of special interest because changes ... as Alzheimer,s, mental illness and aging. "We,ve ...
... have in common? Based on work by scientists at the European ... same part of the brain reacts to both. In a study ... at least in mice different types of fear are ... out those fears in the same way. The findings could have ...
Cached Biology News:New cause found for muscle-weakening disease myasthenia gravis 2New cause found for muscle-weakening disease myasthenia gravis 3SIGNAL found to enhance survival of new brain cells 2What are you scared of? 2
... variety of solvent vapors that can contaminate and ... (GCF400) allows for the collection of liquid into ... cooling time minimizes waiting period., , Easy ... , -50?C Temerature for ...
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... Effectively condenses and traps a wide variety of ... oil. Easy-to-use glass condensation flask (GCF400) allows for the ... easy draining. Rapid cooling time minimizes waiting period., ... high volatile solvents , ...
Biology Products: